KYKOF (Kyowa Kirin Co) 10-Year RORE % : 7.17% (As of Dec. 2025)


KYKOF Kyowa Kirin Co Ltd KYKOF
82 GF Score
Price $14.43
GF Value $17.76
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Kyowa Kirin Co 10-Year RORE %?

Kyowa Kirin Co KYKOF 82 10-Year RORE % is 7.17 as of Dec. 2025. GuruFocus rates KYKOF with a GF Score™ of 82/100 and a GF Value™ of $17.76 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 671 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 66.02% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Kyowa Kirin Co's 10-Year RORE % for the quarter that ended in Dec. 2025 was 7.17%.

The industry rank for Kyowa Kirin Co's 10-Year RORE % or its related term are showing as below:

KYKOF's 10-Year RORE % is ranked better than
66.02% of 671 companies
in the Drug Manufacturers industry
Industry Median: 6.43 vs KYKOF: 7.17

Kyowa Kirin Co  (OTCPK:KYKOF) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Kyowa Kirin Co 10-Year RORE % Related Terms


Kyowa Kirin Co 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for Kyowa Kirin Co's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyowa Kirin Co 10-Year RORE % Chart

Kyowa Kirin Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.75 5.08 18.22 6.49 7.17

Kyowa Kirin Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.17 0.44 3.04 7.17 0.00

KYKOF vs ZTS, UTHR: 10-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyowa Kirin Co 10-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Kyowa Kirin Co's 10-Year RORE % falls into.


KYKOF
82GF Score
Kyowa Kirin Co Ltd KYKOF
10-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyowa Kirin Co 10-Year RORE % Calculation

Kyowa Kirin Co's 10-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( 0.911-0.574 )/( 8.389-3.554 )
=0.337/4.835
=6.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of 7.17 mean?
Kyowa Kirin Co (KYKOF) has a 10-Year RORE % of 7.17 as of Dec. 2025. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Kyowa Kirin Co and its competitors. According to the industry distribution chart, Kyowa Kirin Co ranks #228 out of 671 companies in the Drug Manufacturers industry, placing it in the top 34%.
Is Kyowa Kirin Co's 10-Year RORE % too high?
Kyowa Kirin Co's current 10-Year RORE % is 7.17. The Drug Manufacturers industry median 10-Year RORE % is 6.43. Kyowa Kirin Co's value of 7.17 is 11.5% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #228 out of 671 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kyowa Kirin Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's 10-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #228 out of 671 companies for 10-Year RORE %. This puts Kyowa Kirin Co in the upper half of its industry. The industry median 10-Year RORE % is 6.43. Kyowa Kirin Co's value of 7.17 is 11.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Drug Manufacturers company?
The median 10-Year RORE % among Drug Manufacturers companies is 6.43, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current 10-Year RORE % of 7.17 is 11.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median 10-Year RORE % is 6.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current 10-Year RORE % is 7.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $17.76, compared to a current price of $14.43 — trading 18.8% below its estimated fair value. The current 10-Year RORE % is 7.17 and 11.5% above the Drug Manufacturers industry median of 6.43. Kyowa Kirin Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current 10-Year RORE % is 7.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?

Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued. The current stock price of $14.43 is trading 18.8% below its estimated GF Value™ of $17.76. GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.

Key valuation signals for KYKOF:

  • 10-Year RORE %: 7.17
  • GF Value™: $17.76 vs. price of $14.43 (18.8% below fair value)
  • GF Score™: 82/100 with 1 warning sign
  • Industry Position: 11.5% above the Drug Manufacturers median (#228 of 671)

No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyowa Kirin Co Business Description

Address 1-9-2 Otemachi, Chiyoda-ku, Chiyoda-ku, Tokyo, JPN, 100-0004
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
82GF Score

Get the complete analysis for KYKOF

10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.43
Price
$17.76
GF Value